Condition: Chronic Kidney Disease With High Proteinuria · Sponsor: AstraZeneca
A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants with Chronic Kidney Disease and High Proteinuria
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Aramil, Russia | Recruiting |
| Research Site | Izhevsk, Russia | Suspended |
| Research Site | Krasnoyarsk, Russia | Recruiting |
| Research Site | Moscow, Russia | Suspended |
| Research Site | Moscow, Russia | Recruiting |
| Research Site | Moscow, Russia | Recruiting |
| Research Site | Moscow, Russia | Recruiting |
| Research Site | Omsk, Russia | Recruiting |
| Research Site | Orenburg, Russia | Recruiting |
| Research Site | Perm, Russia | Recruiting |
| Research Site | Saint Petersburg, Russia | Suspended |
| Research Site | Saratov, Russia | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06942910